United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer stock skidded Thursday after former executives Ian Read and Frank D'Amelio sided with the drugmaker over activist investor Starboard.

Pfizer Skids After Former Execs Flip On Activist Investor, Siding With CEO Albert Bourla

Activist Starboard Value accused Pfizer of threatening litigation against two renegade former executives that initially were supportive of the investor's turnaround campaign at the pharmaceutical giant. Starboard's Jeff Smith called on the company to assemble a special committee to investigate the matter, describing it as "flagrantly unethical.

Pfizer threatened to sue renegade executives prior to activist schism, Starboard's Smith says

NEW YORK--(BUSINESS WIRE)--Starboard Value LP (together with its affiliates, “Starboard” or “we”), a significant shareholder of Pfizer Inc. (NYSE: PFE) (“Pfizer” or the “Company”), today issued the below letter to Company's Board of Directors. *** October 10, 2024 Pfizer Inc. 66 Hudson Boulevard East New York, New York 10001 Attn: Board of Directors CC: Doug Lankler, General Counsel Dear Members of the Board, As you know, Starboard Value LP (together with its affiliates, “Starboard” or “we”) is.

Starboard Value Issues Letter to Pfizer's Board of Directors

Pfizer Inc.'s stock dipped early Thursday, after two of its former executives said they would not support an effort by activist shareholder Starboard Value to orchestrate a turnaround.

Pfizer's stock dips after two former execs say they won't support Starboard, offer backing for CEO Albert Bourla

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in patients with metastatic castration-resistant prostate cancer (mCRPC). Results showed a statistically significant and clinically meaningful improvemen.

Pfizer's TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a late-stage study.

Pfizer's cancer drug combo improves overall survival in late-stage study

Transmedics Group Inc

Both of these stocks should have plenty of room to run.

2 No-Brainer Healthcare Stocks to Buy With $200 Right Now

Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with activist investor Starboard Value, which wants the U.S. drug giant to make changes to turn its performance around.

Former Pfizer executives not involved in Starboard's campaign against drugmaker

Two former Pfizer executives who were previously linked to activist investor Starboard Value's campaign at the struggling drugmaker said they would step back from the push late Wednesday evening. Former CEO Ian Read and ex-CFO Frank D'Amelio voiced their full support for current CEO Albert Bourla and the management team.

Former Pfizer CEO, finance chief step back from Starboard's activist campaign

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Guggenheim Securities, LLC is issuing a statement on behalf of former Pfizer CEO Ian Read and former Pfizer CFO Frank D'Amelio: We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer Chairman & CEO Albert Bourla, senior management and the board, and we are confident that over time they will deliver shareholder value.

Statement From Former Pfizer CEO Ian Read and Former Pfizer CFO Frank D'Amelio Regarding Starboard Value

The sharp, sudden entry of an activist investor is raising hopes that change might come to the company.

Why Pfizer Stock Popped Today

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the company's common stock, payable December 2, 2024, to holders of the Common Stock of record at the close of business on November 8, 2024. The fourth-quarter 2024 cash dividend will be the 344th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to.

Pfizer Declares Fourth-Quarter 2024 Dividend

Pfizer (PFE, Financial) experienced a 2.3% increase, reaching $29.85. The rise follows news that Pfizer's CEO plans to meet next week with key leaders from activist investor Starboard Value.

Pfizer (PFE) Surges Amid Investor Talks and Legal Victory

The story of activist fund Starboard Value taking a $1 billion position in Pfizer is grabbing headlines the last few days. However, no good new solutions are being offered, at least according to the stories and articles that have surfaced since the stake was first mentioned. Additional cost cutting, more share repurchases, or management and board changes are unlikely to make a change for the better at Pfizer.

Pfizer: Investor Activism Is Not The Solution

Ken Griffin's Citadel continues to add to its position in Pfizer.

Billionaire Ken Griffin Just Bought 7.9 Million Shares of This Beaten-Down Pharmaceutical Stock as It Eyes the Weight Loss Market

Pfizer (PFE) Chief Executive Officer (CEO) Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion stake in the struggling drugmaker.

Pfizer CEO Bourla to Meet Activist Investor Starboard, Report Says

Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period.

What's Happening With Pfizer Stock?

Starboard will look to turn around the struggling pharma company.

As a Billionaire Activist Takes a Stake, Is Now the Time to Buy Pfizer Stock?

CVS Health

Activists appear to be calling a bottom on the two stocks.

Pfizer and CVS Are Attracting Activists. Healthcare Stocks Could Rebound.

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing people familiar with the matter.

Pfizer CEO plans to meet activist investor Starboard Value, FT reports

Pfizer's troubles may finally be coming to a head. Meanwhile, Hims & Hers is joining S&P SmallCap 600.

Healthy Returns: What activist Starboard's $1 billion stake means for Pfizer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Data in 49 abstracts from company- and collaborator-led studies, will highlight the advances Pfizer is making in helping prevent and treat infectious diseases. “Pfizer is at the forefront of vaccine and therapeutic development in respiratory and infectious diseases,” said Annaliesa Anderson, Ph.D., Senior.

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.

Pfizer Receives $1 Billion From Starboard Value, Stock Rises

Coca-Cola

Realty Income Corp

Here's a little twist for those who like to focus on fundamentals and economic forces when predicting the stock market. When inflation runs hot, it benefits stocks overall, and the opposite is true.

3 Stocks Set to Benefit from Cooling Inflation Trends

Pfizer's (PFE, Financial) stock experienced a boost on Monday, surging by 3 %, following the news that activist investor Starboard Value has acquired a substantial stake in the pharmaceutical giant. The investment, valued at approximately $1 billion, could regain investor confidence in Pfizer.

News for Pfizer Stock (PFE)